2021
Psychotherapy-supported MDMA treatment for PTSD
Krystal JH, Kelmendi B, Petrakis IL. Psychotherapy-supported MDMA treatment for PTSD. Cell Reports Medicine 2021, 2: 100378. PMID: 34467253, PMCID: PMC8385322, DOI: 10.1016/j.xcrm.2021.100378.Peer-Reviewed Original Research
2016
RANDOMIZED TRIAL OF D‐CYCLOSERINE ENHANCEMENT OF COGNITIVE‐BEHAVIORAL THERAPY FOR PANIC DISORDER
Otto MW, Pollack MH, Dowd SM, Hofmann SG, Pearlson G, Szuhany KL, Gueorguieva R, Krystal JH, Simon NM, Tolin DF. RANDOMIZED TRIAL OF D‐CYCLOSERINE ENHANCEMENT OF COGNITIVE‐BEHAVIORAL THERAPY FOR PANIC DISORDER. Depression And Anxiety 2016, 33: 737-745. PMID: 27315514, PMCID: PMC5958622, DOI: 10.1002/da.22531.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntimetabolitesCognitive Behavioral TherapyCombined Modality TherapyCycloserineDouble-Blind MethodFemaleHumansMaleMiddle AgedPanic DisorderTreatment OutcomeYoung AdultConceptsCognitive behavioral therapyBenzodiazepine usePanic disorderDCS augmentationMulticenter trialD-cycloserineRecent multicenter trialPanic Disorder Severity ScaleExposure-based cognitive-behavioral therapySessions of treatmentStudy pillsPrimary outcomeRandomized trialsBaseline severityPrimary diagnosisAugmentation effectTreatment responseTreatment endpointBooster sessionsSeverity ScaleRole of severityBehavioral therapyDCS efficacyBeneficial effectsPilot study
2013
Temporal patterns of adherence to medications and behavioral treatment and their relationship to patient characteristics and treatment response
Gueorguieva R, Wu R, Krystal JH, Donovan D, O'Malley SS. Temporal patterns of adherence to medications and behavioral treatment and their relationship to patient characteristics and treatment response. Addictive Behaviors 2013, 38: 2119-2127. PMID: 23435273, PMCID: PMC3595348, DOI: 10.1016/j.addbeh.2013.01.024.Peer-Reviewed Original ResearchConceptsPercent heavy drinking daysAdherence trajectoriesExcellent adherersPercent days abstinentPatient characteristicsMedication adherenceTreatment outcomesMedication adherence trajectoriesPatterns of treatmentHeavy drinking daysPatterns of adherenceExcellent medication adherenceLack of benefitTrajectories of adherenceIntervention main effectsActive medicationAdverse eventsPharmacologic treatmentHigher percent days abstinentTreatment adherenceTreatment modalitiesWorse outcomesTreatment responseDays abstinentDrinking days
2011
Baseline trajectories of heavy drinking and their effects on postrandomization drinking in the COMBINE Study: empirically derived predictors of drinking outcomes during treatment
Gueorguieva R, Wu R, Donovan D, Rounsaville BJ, Couper D, Krystal JH, O’Malley S. Baseline trajectories of heavy drinking and their effects on postrandomization drinking in the COMBINE Study: empirically derived predictors of drinking outcomes during treatment. Alcohol 2011, 46: 121-131. PMID: 21925828, PMCID: PMC3266454, DOI: 10.1016/j.alcohol.2011.08.008.Peer-Reviewed Original ResearchConceptsDaily heavy drinkersFrequent heavy drinkersHeavy drinkersHeavy drinkingDrinking outcomesAlcohol-dependent patientsBehavioral intervention studyHeavy drinking trajectoriesSummary drinking measuresBaseline characteristicsActive treatmentSevere baselineCombined PharmacotherapiesWorse outcomesPharmacological interventionsCOMBINE StudyIntervention studiesPatientsTreatment factorsDrinkersOutcomesTrajectory membershipDrinking measuresTreatment effectsDrinking
2009
Naltrexone and combined behavioral intervention effects on trajectories of drinking in the COMBINE study
Gueorguieva R, Wu R, Donovan D, Rounsaville BJ, Couper D, Krystal JH, O’Malley S. Naltrexone and combined behavioral intervention effects on trajectories of drinking in the COMBINE study. Drug And Alcohol Dependence 2009, 107: 221-229. PMID: 19969427, PMCID: PMC2821955, DOI: 10.1016/j.drugalcdep.2009.10.017.Peer-Reviewed Original Research
2008
A Meta-Analysis of D-Cycloserine and the Facilitation of Fear Extinction and Exposure Therapy
Norberg MM, Krystal JH, Tolin DF. A Meta-Analysis of D-Cycloserine and the Facilitation of Fear Extinction and Exposure Therapy. Biological Psychiatry 2008, 63: 1118-1126. PMID: 18313643, DOI: 10.1016/j.biopsych.2008.01.012.Peer-Reviewed Original ResearchConceptsExposure therapyFear extinctionD-cycloserineNMDA receptor functionPartial N-methyl-d-aspartate (NMDA) receptor agonistEffects of DCSExposure-based therapyExposure-based treatmentsFear memory consolidationReceptor functionN-methyl-D-aspartate receptor agonistMemory consolidationDCS doseTranslational researchExposure procedureTherapy literatureEnglish-language journal articlesReceptor agonistQuantitative reviewTrial designMeta-AnalysisTherapyStudy authorsTypes of subjectsEffective agent
2007
Neuroplasticity as a Target for the Pharmacotherapy of Psychiatric Disorders: New Opportunities for Synergy with Psychotherapy
Krystal JH. Neuroplasticity as a Target for the Pharmacotherapy of Psychiatric Disorders: New Opportunities for Synergy with Psychotherapy. Biological Psychiatry 2007, 62: 833-834. PMID: 17916459, DOI: 10.1016/j.biopsych.2007.08.017.Peer-Reviewed Original ResearchMeSH KeywordsCombined Modality TherapyCycloserineDrug DesignExcitatory Amino Acid AgentsHumansMental DisordersNeuronal PlasticityPsychotherapyStereoisomerism
2005
Untangling depression and anxiety: clinical challenges.
Keller MB, Krystal JH, Hen R, Neumeister A, Simon NM. Untangling depression and anxiety: clinical challenges. The Journal Of Clinical Psychiatry 2005, 66: 1477-84. PMID: 16420087, DOI: 10.4088/jcp.v66n1119.Peer-Reviewed Original Research
2001
Naltrexone in the Treatment of Alcohol Dependence
Krystal J, Cramer J, Krol W, Kirk G, Rosenheck R. Naltrexone in the Treatment of Alcohol Dependence. New England Journal Of Medicine 2001, 345: 1734-1739. PMID: 11742047, DOI: 10.1056/nejmoa011127.Peer-Reviewed Original ResearchConceptsMonths of placeboSevere alcohol dependenceAlcohol dependencePlacebo-controlled evaluationUse of naltrexoneOpiate receptor antagonistTreatment of menSignificant differencesPercentage of daysStudy medicationNaltrexone groupPlacebo groupNumber of drinksAlcoholics Anonymous meetingsPsychosocial treatmentsNaltrexoneDrug AdministrationPatientsMonthsIndividual counselingNumber of daysPlaceboTreatmentWeeksDays
1994
Psychobiologic Research in Post-Traumatic Stress Disorder
Southwick S, Bremner D, Krystal J, Charney D. Psychobiologic Research in Post-Traumatic Stress Disorder. Psychiatric Clinics Of North America 1994, 17: 251-264. PMID: 7937357, DOI: 10.1016/s0193-953x(18)30112-6.Peer-Reviewed Original ResearchConceptsNeurobiologic responsesCentral nervous system depressantsCentral catecholamine functionPeripheral nervous systemPost-traumatic stress disorderSymptoms of hyperarousalSevere psychological traumaCatecholamine functionOriginal insultNoradrenergic systemMultiple symptomsDevastating disorderEffective treatmentNervous systemPTSD patientsBiologic underpinningsStress-induced changesStress disorderPhysical healthBrain imagingBiologic responseDisordersPatientsPsychological disordersPTSD
1993
Long-Term Outcome of Panic Disorder After Short-Term Imipramine and Behavioral Group Treatment
NAGY L, KRYSTAL J, CHARNEY D, MERIKANGAS K, WOODS S. Long-Term Outcome of Panic Disorder After Short-Term Imipramine and Behavioral Group Treatment. Journal Of Clinical Psychopharmacology 1993, 13: 16-24. PMID: 8098050, DOI: 10.1097/00004714-199302000-00003.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgoraphobiaBehavior TherapyCombined Modality TherapyDesensitization, PsychologicFemaleFollow-Up StudiesHumansImipramineMalePanic DisorderPsychotherapy, GroupConceptsMonths of treatmentLong-term outcomesTime of admissionTime of dischargeEfficacy of treatmentPanic attack frequencyDSM-III diagnosesBehavioral treatment programBehavioral group treatmentNonpharmacological therapiesTerm outcomesMajor depressionAntipanic medicationSame doseLow doseLifetime diagnosisTreatment durationPatientsPanic disorderPanic attacksAttack frequencyImipramineTreatment programBehavioral therapyImpairment ratings
1989
Clinical and Medication Outcome After Short-term Alprazolam and Behavorial Group Treatment in Panic Disorder: 2.5-Year Naturalistic Follow-up Study
Nagy LM, Krystal JH, Woods SW, Charney DS. Clinical and Medication Outcome After Short-term Alprazolam and Behavorial Group Treatment in Panic Disorder: 2.5-Year Naturalistic Follow-up Study. JAMA Psychiatry 1989, 46: 993-999. PMID: 2818144, DOI: 10.1001/archpsyc.1989.01810110035005.Peer-Reviewed Original ResearchConceptsFU periodAlprazolam treatmentMajor depressionPanic disorderPanic attacksPanic attack frequencyBehavioral group treatment programGreater symptom severityAntipanic effectsNonpharmacologic therapiesMedication outcomesNaturalistic followGroup treatment programAlprazolam dosesSame doseLow doseLifetime diagnosisAttack frequencySymptom severityTreatment programBehavioral therapyPatientsAdmissionAlprazolamTreatment gains